Ian F. Tannock
Led TAX 327, which made docetaxel the first life-extending chemotherapy for prostate cancer, and has spent decades pressing for higher trial standards.
Overview
Ian Tannock was principal investigator of TAX 327, the trial showing docetaxel improves survival in metastatic castration-resistant prostate cancer, the first chemotherapy to do so. He co-authored the textbook The Basic Science of Oncology, helped create the ESMO Magnitude of Clinical Benefit Scale, and has been a leading critic of trials that rely on surrogate endpoints, control-arm deficiencies and inadequate quality-of-life reporting. He is a founder of Common Sense Oncology.
| Title | Journal | Year |
|---|---|---|
| Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer (TAX 327) | NEJM | 2004 |
| Relevance of randomised controlled trials in oncology | Lancet Oncology | 2016 |
The dose on the label is often not the best dose for patients; it is the highest one that was tolerable for a few weeks. Project Optimus means new cancer drugs should arrive with evidence on dose, and it gives clinicians licence to consider dose reduction for toxicity. For older drugs, the evidence gap persists.
A drug that shrinks tumours or delays progression on scans has not necessarily been shown to help patients live longer or better. Patients and clinicians should ask what the endpoint was; regulators should insist on timely confirmatory trials; and trialists should validate surrogates before relying on them.
Pages like this
not linked directly; found by shared links- PersonChristopher M. Booth
Shares Prasad: most surrogate endpoints in cancer trials correlate poorly with survival and the tag evidence.
- TrialCHAARTED (E3805)
Shares Docetaxel, Prostate cancer.
- TrialPEACE-1
Shares Docetaxel, Prostate cancer.
- TrialARASENS
Shares Docetaxel, Prostate cancer.
- PersonMatthew R. Smith
Shares Prostate cancer and the tag prostate.
- PersonAndrew J. Armstrong
Shares Prostate cancer and the tag prostate.
- PersonAnthony V. D'Amico
Shares Prostate cancer and the tag prostate.
- PersonFreddie C. Hamdy
Shares Prostate cancer and the tag prostate.